Payment overview · 2025
General Payments
$94.50
5 reported records · 3 companies
Healthcare provider profile · identity verified
Craig M Bogdanski, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · SOUTHINGTON, CT · NPI 1710986906
Verified facts
What the public records show
CMS Open Payments records show Craig M Bogdanski, D.O. received $94.50 in general payments during 2025 across 5 reported records.
Novartis Pharmaceuticals Corporation accounted for 65.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $62.03 | 65.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.06 | 18.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.41 | 16.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $94.50 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $62.03 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
166 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1045 | 243 |
| Amlodipine Besylate | Amlodipine Besylate | 578 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 552 | 113 |
| Eliquis | Apixaban | 419 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 374 | 73 |
| Losartan Potassium | Losartan Potassium | 362 | 76 |
| Trazodone Hcl | Trazodone Hcl | 322 | 54 |
| Gabapentin | Gabapentin | 293 | 52 |
| Furosemide | Furosemide | 289 | 67 |
| Metformin Hcl | Metformin Hcl | 285 | 71 |
| Sertraline Hcl | Sertraline Hcl | 276 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 268 | 61 |
| Lisinopril | Lisinopril | 263 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 256 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 214 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 193 | 31 |
| Ezetimibe | Ezetimibe | 181 | 45 |
| Potassium Chloride | Potassium Chloride | 167 | 30 |
| Jardiance | Empagliflozin | 166 | 36 |
| Donepezil Hcl | Donepezil Hcl | 165 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 163 | 35 |
| Mirtazapine | Mirtazapine | 152 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 34 |
| Omeprazole | Omeprazole | 133 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 41 |
| Warfarin Sodium | Warfarin Sodium | 109 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 17 |
| Allopurinol | Allopurinol | 98 | 23 |
| Simvastatin | Simvastatin | 95 | 20 |
| Januvia | Sitagliptin Phosphate | 93 | 15 |
| Memantine Hcl | Memantine Hcl | 86 | 13 |
| Glipizide | Glipizide | 79 | 18 |
| Xarelto | Rivaroxaban | 77 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 22 |
| Prednisone | Prednisone | 72 | 24 |
| Spironolactone | Spironolactone | 62 | 15 |
| Atenolol | Atenolol | 61 | 17 |
| Buspirone Hcl | Buspirone Hcl | 61 | suppressed |
| Lorazepam | Lorazepam | 61 | 19 |
| Finasteride | Finasteride | 59 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 18 |
| Levetiracetam | Levetiracetam | 56 | suppressed |
| Ozempic | Semaglutide | 55 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 52 | 15 |
| Gemtesa | Vibegron | 50 | suppressed |
| Amoxicillin | Amoxicillin | 49 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 12 |
| Alprazolam | Alprazolam | 48 | 13 |
| Klor-Con 10 | Potassium Chloride | 48 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 42 |
| Famotidine | Famotidine | 43 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 42 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 40 | 14 |
| Carvedilol | Carvedilol | 39 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Bumetanide | Bumetanide | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Ketoconazole | Ketoconazole | 37 | 14 |
| Olanzapine | Olanzapine | 37 | suppressed |
| Torsemide | Torsemide | 35 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | 13 |
| Midodrine Hcl | Midodrine Hcl | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | 12 |
| Methylprednisolone | Methylprednisolone | 31 | 29 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 28 | 24 |
| Olanzapine Odt | Olanzapine | 28 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 20 |
| Primidone | Primidone | 24 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 12 |
| Trimethoprim | Trimethoprim | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Nystatin | Nystatin | 22 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 14 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Acetic Acid | Acetic Acid | 19 | suppressed |
| Cefadroxil | Cefadroxil | 19 | 15 |
| Gvoke Hypopen 1-Pack | Glucagon | 19 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Admelog Solostar | Insulin Lispro | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | 13 |
| Silodosin | Silodosin | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Admelog | Insulin Lispro | 12 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 12 | 11 |
| Baclofen | Baclofen | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $94.50 · 5 records | Novartis Pharmaceuticals Corporation | AREXVY, LEQVIO, MOUNJARO, SHINGRIX, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error